EZH2 and prostate carcinoma: Consistent with these findings, phosphorylation of the serine 21 EZH2 residue has been shown to be required for the interaction of EZH2 with other transcriptional regulators, such as the androgen receptor and STAT3 in prostate cancer [21] and glioblastoma [27], respectively.